We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma
News

BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma

BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma
News

BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioInvent International AB presents preclinical data demonstrating anti-tumour activity of its therapeutic cancer antibody BI-505 targeting ICAM-1. The data, presented at the XIIth International Myeloma Workshop in Washington DC, demonstrates that the compound is more efficacious in prolonging survival in animal models compared to bortezomib.

The drug launched in 2003 for treatment of multiple myeloma, has shown strong performance in a market with estimated 40,000 new cases annually globally.

BI-505 is a fully human monoclonal antibody derived from BioInvent’s proprietary antibody library n-CoDeR®. BI-505 was recently granted orphan drug designation by the European Agency for the Evaluation of Medicines (EMEA) for multiple myeloma, having previously been awarded Orphan Drug designation by the FDA in the US market. It is anticipated that the antibody could have an important role in the refractory or relapsed setting, due to up-regulation of ICAM-1 in patients who have developed resistance to chemotherapy.

The research to date suggests that by targeting ICAM-1, an adhesion molecule that is highly expressed in tumour cells, BI-505 directly inhibits tumour cell growth by inducing cell death through direct cell cytotoxicity (apoptosis) and also antibody dependent cell-mediated cytotoxicity (ADCC).

Svein Mathisen, CEO of BioInvent, commented, “We believe BI-505 will address a major unmet medical need in multiple myeloma. The antibody has demonstrated exciting pre-clinical results and we look forward to proceeding with a Phase I trial mid-2009. Due to upregulation of ICAM-1 in patients who have developed resistance and BI-505’s mechanism of action, we believe that BI-505 could make an important contribution to treatment options for patients with refractory and relapsed myeloma.”
Advertisement